WithdrawnPhase 1NCT04585711

Pharmacokinetics and Pharmacodynamics of Biologic Drugs in Obese Patients With Arthritis

Studying Juvenile idiopathic arthritis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Duke University
Principal Investigator
Stephen Balevic, MD
Duke Clinical Research Institute
Intervention
Etanercept Optimal dosing(drug)
Eligibility
2-65 years · All sexes
Timeline
2026 – 2027

Study locations (1)

Collaborators

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04585711 on ClinicalTrials.gov

Other trials for Juvenile idiopathic arthritis

Additional recruiting or active studies for the same condition.

See all trials for Juvenile idiopathic arthritis →

← Back to all trials